Sign in to view content

12-Month Ocular Pharmacokinetic Study of EYP-1901 a Sustained-Release Intravitreal Formulation of the Tyrosine Kinase Inhibitor Vorolanib

Rishi P. Singh, MD

Video
Published 2023

Related

Faricimab Reduces Macular Leakage vs Aflibercept in Patients With DME
Eric Nudleman, MD, PhD
Annual Meeting Talks
2023
Port Delivery System with Ranibizumab PDS for Continuous Treatment in DME and DR Additional Results from the Phase 3 Pagoda and Pavilion Trials
Dennis M. Marcus, MD
Annual Meeting Talks
2023
First Time Results of VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy
Omer Trivizki, MD, MBA
Updates from the Field
2025

Category: Pharmacology

See more